New scan agent shows promise for spotting prostate cancer
NCT ID NCT06840535
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 24 times
Summary
This study tested a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal was to see if it is safe and how much radiation the body receives. The agent helps doctors see cancer spots that other scans might miss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Papa Giovanni XXIII
Bergamo, BG, 24127, Italy
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Milano, 20133, Italy
-
IRCCS Ospedale San Raffaele
Milan, Milano, 20132, Italy
Conditions
Explore the condition pages connected to this study.